DPDaily Peptide

MELANOTAN II · DECODED

← Back to Decoded
NEVER APPROVED ANYWHERENON-SELECTIVE · MC1R MC3R MC4RGREY MARKET

Melanotan II

Decoded · Never Approved · Grey Market · Non-Selective MC Agonist

MT-II led to an approved drug. MT-II itself was never the approved drug. Melanotan II was the parent compound that revealed the MC4R receptor's role in sexual arousal, research that directly produced bremelanotide (PT-141), FDA-approved in 2019 for female sexual dysfunction. MT-II itself was never approved anywhere. It is non-selective, hitting MC1R, MC3R, and MC4R simultaneously, which is why it produces tanning, appetite suppression, and sexual arousal at once.

BY THE NUMBERS

7
AMINO ACIDS · CYCLIC PEPTIDE ANALOG OF α-MSH
0
FDA APPROVALS · NEVER APPROVED ANYWHERE
2019
YEAR ITS DESCENDANT BREMELANOTIDE/PT-141 WAS FDA APPROVED
3
MELANOCORTIN RECEPTORS ACTIVATED: MC1R, MC3R, MC4R

HOW IT WORKS

Non-selective melanocortin agonist with significant activity at MC1R (tanning/pigmentation), MC3R (metabolic and anti-inflammatory effects), and MC4R (sexual arousal, appetite suppression, erectile function). The MC4R pathway activity directly led to the development and FDA approval of bremelanotide/PT-141 for female sexual interest and arousal disorder (FSIAD) in 2019. Melanotan II itself was never submitted for regulatory approval.

WHERE IT CAME FROM

Melanotan II (MT-II) was developed alongside Melanotan I at the University of Arizona in the late 1980s and 1990s under Hadley and Hruby's research program. Where Melanotan I is a full-length alpha-MSH analog, MT-II is a shorter cyclic heptapeptide (seven amino acids arranged in a ring structure) designed to be more stable and potent. The structural change was intended to improve pharmacokinetic properties, and it succeeded: MT-II is highly potent. The problem was the breadth of its activity.

MT-II is non-selective across melanocortin receptors. It activates MC1R (pigmentation), MC3R (metabolic regulation and energy balance), and MC4R (sexual arousal, appetite, and autonomic function). This multi-receptor profile meant that early clinical testing in the late 1990s produced simultaneous tanning, erections in male subjects, and appetite suppression, a combination that alarmed clinicians and made it impossible to develop as a pharmaceutical product with an acceptable side effect profile. However, the MC4R finding was scientifically valuable: it established that the MC4R receptor could drive sexual arousal, which led directly to the development of bremelanotide (PT-141), a more selective MC4R agonist that was FDA-approved in 2019 for hypoactive sexual desire disorder in premenopausal women.

THE STUDIES

Late 1990s
Early human trials: tanning and sexual effects: The first human trials of Melanotan II in the late 1990s confirmed its potency but also confirmed the problem: simultaneous tanning, spontaneous erections, and appetite suppression in the same subjects. Male volunteers experienced unsolicited erections that persisted for several hours. These trials established the mechanism but also the clinical impracticality of MT-II as a pharmaceutical. The erection data was not an intended finding. Researchers were testing a tanning agent. The sexual arousal connection, once identified, became the basis for the PT-141 (bremelanotide) development program.
2019
Bremelanotide (PT-141): FDA Approved Descendant: PT-141, or bremelanotide, is a derivative of Melanotan II designed to selectively target MC4R for sexual arousal while minimizing other melanocortin receptor effects, particularly the blood pressure-raising and tanning effects. FDA approved bremelanotide in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. This is the legitimate pharmaceutical descendant of the MT-II research. MT-II itself was not developed further because its multi-receptor activity created an unacceptable side effect burden.
Ongoing concern
Melanocytic nevi risk: A documented concern with Melanotan II use is the development of new melanocytic nevi (moles) or changes in existing nevi. Because MT-II activates MC1R broadly and drives melanocyte stimulation, it can promote the proliferation of melanocytes in ways that affect existing moles and potentially contribute to new lesion formation. This is not a theoretical risk. It has been documented in case reports of MT-II users. Any new or changing mole in someone using MT-II requires dermatological evaluation. This is not a risk to minimize or dismiss.

WHAT THE STUDIES SHOW

ESTABLISHED

  • ▸MC1R: tanning and eumelanin production (confirmed mechanism)
  • ▸MC4R: sexual arousal in humans (confirmed in early trials)
  • ▸Non-selective: MC1R, MC3R, MC4R simultaneously activated
  • ▸PT-141/bremelanotide: FDA-approved descendant from this mechanism

DOCUMENTED RISK

  • ▸New melanocytic nevi (moles): documented in case reports
  • ▸Changes in existing moles: do NOT minimize this
  • ▸Nausea: dose-dependent, documented in trials
  • ▸Spontaneous/prolonged erections in male users: documented in trials

UNKNOWN / UNAPPROVED

  • ▸Long-term melanocytic safety with chronic use
  • ▸Appetite suppression: magnitude and safety in humans not characterized
  • ▸Blood pressure effects at grey market doses
  • ▸Safe and effective dose range in any indication

SIDE EFFECTS

DOCUMENTED (TRIAL + CASE REPORTS)

  • ▸Nausea: dose-dependent, one of the most common complaints
  • ▸Spontaneous erections (males)
  • ▸Facial flushing
  • ▸Fatigue and drowsiness
  • ▸Blood pressure changes

NOTABLE / DO NOT IGNORE

  • ▸New melanocytic nevi: documented. Requires dermatological monitoring.
  • ▸Changes in existing moles: documented. See a dermatologist if moles change.
  • ▸Non-selective receptor activation: the same mechanism that causes tanning also causes the sexual and appetite effects. They cannot be separated.
  • ▸Never approved: no regulated supply, no purity verification, no safe dose defined

REGULATORY STATUS

FDA STATUS
Never approved · Category 2 removal · PCAC Meeting #2 before Feb 2027
PHASE
No approved indication · PT-141 (bremelanotide) is the approved descendant
PROJECTED NDA
None · MT-II was abandoned in development; PT-141 took the approved route

Melanotan II has never been approved by the FDA, EMA, or any major regulatory authority, and no pharmaceutical company has an active program to bring it to approval. It was on the FDA's Category 2 prohibited list, which was partially lifted on April 15, 2026. Melanotan II was among the 12 compounds removed from Category 2 prohibition. The PCAC is scheduled to review it and four other compounds before February 2027 (PCAC Meeting #2). Removal from Category 2 does not authorize compounding. The legitimate pharmaceutical descendant of MT-II's mechanism, bremelanotide (Vyleesi, FDA 2019), is commercially available for HSDD by prescription.

PROS & CONS

PROS

  • +Mechanism is well-characterized and real: MC1R and MC4R activation produce documented effects
  • +Its pharmacology contributed to the development of an FDA-approved drug (bremelanotide)
  • +Tanning effect is documented in human trials (though never approved as an indication)
  • +PCAC review before Feb 2027 may establish a clearer regulatory path

CONS

  • −Never approved anywhere for any indication
  • −New and changing moles: a documented and serious safety concern that must not be minimized
  • −Non-selective: tanning, sexual arousal, appetite suppression, and blood pressure effects cannot be decoupled
  • −Nausea is common and dose-limiting
  • −Grey market supply: no purity, concentration, or sterility verification
  • −Bremelanotide (Vyleesi) is FDA-approved for female sexual dysfunction with completed Phase 3 data; MT-II has no equivalent clinical approval or trial record

DAILY PEPTIDE VERDICT

RANKING

The Compound That Accidentally Built PT-141

Melanotan II's legacy is real but complicated. It revealed the MC4R sexual arousal pathway in humans, which led directly to bremelanotide, an FDA-approved drug that works through the same pathway with a more selective mechanism. MT-II itself affects multiple receptor subtypes simultaneously: MC1R, MC3R, MC4R, and MC5R. The melanocytic nevi risk documented in the non-approval trials is not hypothetical. For tanning, the compound is not FDA-approved and quality depends on the vendor. For sexual function, bremelanotide is an approved alternative available by prescription. Whether the risk-benefit calculation makes sense depends on individual context, available alternatives, and physician input.

Also in MELANOCORTIN (TANNING / LIBIDO)

// MELANOCORTIN (TANNING / LIBIDO)

Melanotan I

FDA APPROVEDPHASE 3+

DISCLAIMER · EDUCATIONAL USE ONLY

This document is for educational and informational purposes only. Melanotan II is sold as a research chemical and does not hold FDA approval for human use. Information here synthesizes publicly available research data and does not constitute medical advice.